Plus Therapeutics (PSTV) to Release Earnings on Thursday

Plus Therapeutics (NASDAQ:PSTV) is expected to release its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect Plus Therapeutics to post earnings of ($0.02) per share and revenue of $1.50 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 5:00 PM ET.

Plus Therapeutics (NASDAQ:PSTV) last issued its earnings results on Thursday, October 30th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The firm had revenue of $1.40 million during the quarter, compared to analyst estimates of $1.50 million. On average, analysts expect Plus Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Plus Therapeutics Trading Up 1.6%

Shares of PSTV stock opened at $0.57 on Wednesday. The company has a market capitalization of $56.56 million, a price-to-earnings ratio of -0.25 and a beta of 0.77. Plus Therapeutics has a 1-year low of $0.16 and a 1-year high of $2.31. The stock’s fifty day simple moving average is $0.57 and its 200-day simple moving average is $0.49.

Insider Transactions at Plus Therapeutics

In other news, Director Robert P. Lenk bought 110,000 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average price of $0.49 per share, for a total transaction of $53,900.00. Following the acquisition, the director directly owned 139,327 shares of the company’s stock, valued at $68,270.23. The trade was a 375.08% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.79% of the company’s stock.

Institutional Investors Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. Jane Street Group LLC acquired a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 117,454 shares of the company’s stock, valued at approximately $41,000. Jane Street Group LLC owned about 0.19% of Plus Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 3.28% of the company’s stock.

Analysts Set New Price Targets

PSTV has been the topic of several research analyst reports. Ascendiant Capital Markets lifted their target price on Plus Therapeutics from $20.50 to $21.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Wednesday, October 8th. HC Wainwright lowered their price objective on shares of Plus Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Monday, November 3rd. Maxim Group dropped their target price on Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, August 18th. Finally, Wall Street Zen raised shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $7.75.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.